U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07435129) titled 'Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD' on Feb. 10.
Brief Summary: A randomized Phase 2 study to evaluate the efficacy and safety of apitegromab as a monotherapy in participant with FSHD
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Facioscapulohumeral Muscular Dystrophy
FSHD
Intervention:
DRUG: Apitegromab
Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion.
DRUG: Placebo
Placebo is admi...